Clinical evaluation of combined programmed cell death protein 1 inhibitor and poly(ADP-ribose) polymerase inhibitor in metastatic castration-resistant prostate cancer patients: Insights from a real-world study
{{output}}
Background: This study aimed to evaluate the clinical efficacy and safety of combining a programmed cell death protein 1 (PD-1) inhibitor with a poly(ADP-ribose) polymerase inhibitor (PARPi) in patients with metastatic castration... ...
